No description available.

Endometrial cancer is one of the most significant gynaecological malignancies that affect women from New Zealand and the rest of the world. One of the critical stages in the development of a tumour is the onset of hypoxia. The malignancy responds by having raised levels of Hypoxia Inducible Factor (HIF) that in turn induces increased production of Vascular Endothelial Growth Factor (VEGF). VEGF is a potent angiogenic factor that will mediate vascular supply of nutrients and oxygen to the developing tumour. The aim of this study was to investigate whether two compounds found in extracts of plant materials, Resveratrol (Resveratrol) and Epigallocatechin gallate (EGCG), altered the levels of VEGF in the supernatant of cultured endometrial cancer cells. Resveratrol is a phytoalexin that is found in many foods, such as grapes, nuts and berries, as well as in high concentrations in some red wines. 100 µM of resveratrol was added to cell cultures for 24 hours. VEGF levels in the supernatant were then analysed using ELISA. Resveratrol was found to have significant inhibitory effects in both primary endometrial cancer cell cultures and immortalised endometrial cancer cell cultures. Resveratrol was also shown to reverse the increase in VEGF caused by the hypoxia mimic cobalt chloride (CoCl₂). Epigallocatechin gallate (EGCG) is an antioxidant catechin extracted from green tea. The effect of EGCG was analysed using the same method as for resveratrol. 100 µM of EGCG was also shown to have a significant inhibitory effect on the level of VEGF in the supernatant of cultured endometrial cancer cells, as well as reducing the effect of CoCl₂. These results suggest that selected food compounds, resveratrol and EGCG, can reduce VEGF levels by inhibiting HIF. Further investigation This may have anti-tumour effects in women with endometrial cancer.

No description available.

No description available.

No description available.

No description available.

No description available.

No description available.

No description available.

Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine cutaneous cancer whose molecular biology is poorly characterized. Our broad research objective is to identify microRNAs (miRNA) that are biologically and/or clinically important in MCC. While attempting to establish an MCC-specific miRNA signature, we observed that microRNA-375 was the most highly expressed miRNA in primary MCC tumours relative to normal skin – an observation that I propose reflects miR-375’s specific association with neuroendocrine (NE) and secretory subpopulations within normal tissues. Here, I report that miR-375 is strikingly elevated in a range of NE tumour types compared with tissue-matched cancers of non-neuroendocrine origin. Furthermore, I show that miR-375 is expressed abundantly in a subset of MCC cell lines that possess the biochemical and immunohistochemical characteristics of NE cells, but is silenced in cell lines that fail to retain these markers. I demonstrate that the enforced expression of miR-375 induces a NE gene expression signature – a phenomenon that is mechanistically driven by the post-transcriptional repression of multiple Notch pathway components by miR-375. This work identifies the Notch pathway as a novel mechanistic link between the association of miR-375 and a NE cell fate, provides new insights into the cellular ancestry of MCC, and suggests that miR-375 could facilitate clinicopathological diagnosis of MCC and other NE tumours as a novel biomarker. miR-375 is silenced in “variant” MCC cell lines, and inversely correlates with cell doubling time and overall aggressiveness. Therefore, despite its high expression in most MCC tumours, I propose that miR-375 is an endogenous tumour suppressor. I show that the enforced expression of miR-375 inhibits cell viability, impairs cell migration and invasion, can oppose survival under stress, and represses the AKT pro-survival signaling pathway. Only siRNA-mediated inhibition of Notch2 and Recombination signal binding protein for immunoglobulin kappa J region (RBPJ) phenocopied the effects of miR-375 overexpression. Because variant (miR-375low) cell lines originate from more aggressive tumours in both MCC and small cell lung carcinoma, I postulate that miR-375 silencing occurs in a subset of MCC patients and might predispose them to a highly virulent clinical course through the disinhibition of Notch signaling. / Thesis (Master, Pathology & Molecular Medicine) -- Queen's University, 2013-08-15 09:59:09.832